December 2020 in “American Journal of Transplantation” Early recognition and treatment of VATS in transplant patients improve outcomes.
28 citations
,
January 2005 in “PubMed” Topical immunomodulators are effective and safe for treating immune-related skin conditions.
47 citations
,
December 2019 in “Frontiers in immunology” A new mutation in the STING protein causes a range of symptoms and its severity may be affected by other genetic variations; treatment with a specific inhibitor showed improvement in one patient.
53 citations
,
September 2020 in “Stem Cell Research & Therapy” New methods to improve the healing abilities of mesenchymal stem cells for disease treatment are promising but need more research.
The nail immune system is similar to hair but different from skin, with fewer immune markers.
Moles may stop growing due to cell cooperation, not just because of individual cell aging.
139 citations
,
October 2005 in “Journal of Investigative Dermatology” The nail matrix has a reduced immune response, protecting it from autoimmunity.
33 citations
,
October 2018 in “BMJ Case Reports” Aggressive treatment in young patients with certain drug reactions may lead to multiple autoimmune diseases later.
114 citations
,
September 1985 in “Journal of Investigative Dermatology” CMV infection increases the risk of GvHD after bone marrow transplants.
5 citations
,
August 1983 in “PubMed” DNA virus-induced tumors have consistent isozyme profiles, unlike other tumor types.
123 citations
,
September 1987 in “JAMA” IL-2 treatment causes skin eruptions and other reversible side effects, and may play a role in psoriasis.
38 citations
,
March 2015 in “Journal of controlled release” IMSG nanoparticles improve vaccine delivery and immune response through hair follicles.
October 2018 in “The American journal of gastroenterology” Pembrolizumab can cause serious liver issues, requiring close monitoring and early treatment.
January 2026 in “Journal of Biomedical Research” Small extracellular vesicles from stem and immune cells show promise for treating various diseases but face challenges in clinical use.
8 citations
,
October 2016 in “Experimental dermatology” Hair follicles may help teach the immune system to tolerate new self-antigens, but this can sometimes cause hair loss.
Immune therapy for cancer can cause rare hair loss but doesn't stop treatment success.
March 2006 in “Drug Discovery Today: Therapeutic Strategies” The 2006 editorial concluded that immunotherapy was advancing with new drugs, focusing on specific biological therapies and convenient oral treatments, and highlighted the importance of partnerships and new regulations in the field.
2 citations
,
October 2022 in “Current Dermatology Reports” People on immune-modifying skin disease treatments may have a weaker antibody response to COVID-19 vaccines but often improve after the second dose.
April 2023 in “Journal of Investigative Dermatology” The research developed methods to test drugs that could protect and restore hair follicle protection in a hair loss condition.
2 citations
,
January 2014 in “Elsevier eBooks” The document concludes that reactivation of herpesviruses, especially HHV-6, is linked to severe symptoms and complications in drug-induced hypersensitivity syndrome.
April 2018 in “Journal of Investigative Dermatology” The role of γδT-cells in causing alopecia areata remains unclear.
3 citations
,
January 2003 in “Cell Structure and Function” Injecting certain cells into mice caused hair loss, which was preventable with a specific inhibitor.
4 citations
,
April 2016 in “Journal of The American Academy of Dermatology” A patient with advanced kidney cancer and no hepatitis C developed skin inflammation due to a drug called interferon alpha-2a.
22 citations
,
March 1999 in “International Journal of Clinical Practice” Diphencyprone (DCP) is an effective treatment for severe alopecia areata and resistant warts, with some risks.
April 2023 in “Journal of Investigative Dermatology” Type 1/17 inflammation in psoriasis increases skin cell growth due to a molecule that could be a new treatment target.
April 2026 in “The Journal of Dermatology” Vitiligo patients have higher risks of autoimmune diseases, infections, and skin cancer.
June 2020 in “Comparative medicine” NSG mice had the most mites, and genetic factors affect immune response and susceptibility.
July 2024 in “Journal of Investigative Dermatology” Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.
10 citations
,
June 2019 in “Transplant infectious disease” The virus linked to a rare disease was found in a patient's blood and urine before skin symptoms appeared.